Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5)

Next Previous
Trial Profile

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oregovomab (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FLORA-5
  • Sponsors CanariaBio; OncoQuest

Most Recent Events

  • 23 Jan 2024 According to a Quest PharmaTech Inc. media release, DSMB expressed, there is a possibility of significant efficacy in overall survival and recommended that follow up observations be continued in study subjects.
  • 23 Jan 2024 According to a Quest PharmaTech Inc. media release, company announced that it has received recommendations from the Data Safety Monitoring Board (DSMB), to discontinue the clinical trial after conducting a futility evaluation for interim progression free survival in study subjects.
  • 12 Oct 2023 According to a Specialised Therapeutics Asia media release,final results of this trial are expected in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top